Previous close | 32.95 |
Open | 32.15 |
Bid | 31.89 x 100 |
Ask | 32.07 x 200 |
Day's range | 31.88 - 32.18 |
52-week range | 31.86 - 45.21 |
Volume | |
Avg. volume | 120,380 |
Market cap | 2.107B |
Beta (5Y monthly) | 0.03 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.54 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 43.55 |
Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation. Andrew Dickinson is Gilead's Chief Financial Officer (CFO) and replaces Daniel O’Day, Gilead’s Chairman and Chief Executive Officer (CEO), who was a member of the Galapagos Board of Directors from 22 October 2019 to 26 March 2024. Mr. Dickinson jo
Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
In this article, we will be taking a look at 11 oversold biotech stocks to buy right now. To skip our detailed analysis of the biotech sector, you can go directly to see the 5 Oversold Biotech Stocks To Buy Right Now. Dealmaking in Biotech Healthcare has been performing well so far in 2024, and […]